259 related articles for article (PubMed ID: 8150756)
41. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
Pottumarthy S; Fritsche TR; Sader HS; Stilwell MG; Jones RN
Int J Antimicrob Agents; 2005 Apr; 25(4):282-9. PubMed ID: 15784306
[TBL] [Abstract][Full Text] [Related]
42. Time-kill evaluation of antimicrobial regimens against clinical isolates of penicillin-resistant Streptococcus pneumoniae.
Bañón Arias R; García López M; Pinedo Sánchez A
J Chemother; 2001 Oct; 13(5):535-40. PubMed ID: 11760218
[TBL] [Abstract][Full Text] [Related]
43. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
44. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae.
Tan TQ; Mason EO; Barson WJ; Wald ER; Schutze GE; Bradley JS; Arditi M; Givner LB; Yogev R; Kim KS; Kaplan SL
Pediatrics; 1998 Dec; 102(6):1369-75. PubMed ID: 9832571
[TBL] [Abstract][Full Text] [Related]
45. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae.
Pikis A; Donkersloot JA; Akram S; Keith JM; Campos JM; Rodriguez WJ
J Antimicrob Chemother; 1997 Jul; 40(1):105-8. PubMed ID: 9249211
[TBL] [Abstract][Full Text] [Related]
46. In-vitro activities of 16 non-beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Verhaegen J; Verbist L
J Antimicrob Chemother; 1999 Apr; 43(4):563-7. PubMed ID: 10350388
[TBL] [Abstract][Full Text] [Related]
47. In vitro activity of oral cephalosporins against pediatric isolates of Streptococcus pneumoniae non-susceptible to penicillin, amoxicillin or erythromycin.
Fenoll A; Giménez MJ; Robledo O; Aguilar L; Tarragó D; Granizo JJ; Gimeno M; Coronel P
J Chemother; 2008 Apr; 20(2):175-9. PubMed ID: 18467242
[TBL] [Abstract][Full Text] [Related]
48. Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis.
Tweardy DJ; Jacobs MR; Speck WT
J Antimicrob Chemother; 1983 Aug; 12(2):133-9. PubMed ID: 6555189
[TBL] [Abstract][Full Text] [Related]
49. Streptococcus pneumoniae resistant to penicillin: incidence and potential therapeutic options.
Rodriguez WJ; Schwartz RH; Akram S; Khan WN
Laryngoscope; 1995 Mar; 105(3 Pt 1):300-4. PubMed ID: 7877420
[TBL] [Abstract][Full Text] [Related]
50. [Resistance to penicillin and other antimicrobials in 301 clinical isolates of Streptococcus pneumoniae].
Navarro C; Egido P; Aspiroz C; Durán E; García C; Rubio C; Gómez-Lus R
Enferm Infecc Microbiol Clin; 2000; 18(7):314-8. PubMed ID: 11109722
[TBL] [Abstract][Full Text] [Related]
51. Comparative susceptibility of Yersinia enterocolitica, Eikenella corrodens, and penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to beta-lactam and alternative antimicrobial agents.
Goldstein EJ; Cherubin CE; Corrado ML; Sierra MF
Rev Infect Dis; 1982; 4 Suppl():S406-10. PubMed ID: 6294791
[TBL] [Abstract][Full Text] [Related]
52. In-vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae.
Manzor O; Pawlak J; Saravolatz L
J Antimicrob Chemother; 1999 Jan; 43(1):31-6. PubMed ID: 10381098
[TBL] [Abstract][Full Text] [Related]
53. Bacterial resistance surveillance in China: a report from Mohnarin 2004-2005.
Xiao YH; Wang J; Li Y;
Eur J Clin Microbiol Infect Dis; 2008 Aug; 27(8):697-708. PubMed ID: 18563461
[TBL] [Abstract][Full Text] [Related]
54. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
Zhanel GG; Yachison C; Nichol K; Adam H; Noreddin AM; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2012 Jul; 67(7):1706-11. PubMed ID: 22467630
[TBL] [Abstract][Full Text] [Related]
55. [Carrier rate of Streptococcus pneumoniae and susceptibility thereof to antimicrobial drugs among children in China: a surveillance study in Beijing, Shanghai, and Guangzhou 2000-2002].
Yao KH; Lu Q; Deng L; Yu SJ; Zhang H; Deng QL; Shen XZ; Yang YH
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(28):1957-61. PubMed ID: 16313770
[TBL] [Abstract][Full Text] [Related]
56. Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in-vitro susceptibility to selected oral antibiotics.
Mason EO; Lamberth L; Lichenstein R; Kaplan SL
J Antimicrob Chemother; 1995 Dec; 36(6):1043-8. PubMed ID: 8821604
[TBL] [Abstract][Full Text] [Related]
57. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
Fenoll A; Aguilar L; Robledo O; Giménez MJ; Tarragó D; Granizo JJ; Gimeno M; Coronel P
J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681
[TBL] [Abstract][Full Text] [Related]
58. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
Spangler SK; Jacobs MR; Pankuch GA; Appelbaum PC
J Antimicrob Chemother; 1993 Feb; 31(2):273-80. PubMed ID: 8463172
[TBL] [Abstract][Full Text] [Related]
59. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Sun H; Chen L; Chen X; Jia X; Li N; Liu W; Tong H; Xiang R; Zhang F; Zhao H; Zhang J; Xu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jan; 39(1):30-7. PubMed ID: 26792053
[TBL] [Abstract][Full Text] [Related]
60. Drug-resistant Streptococcus pneumoniae in the Lebanon: implications for presumptive therapy.
Araj GF; Bey HA; Itani LY; Kanj SS
Int J Antimicrob Agents; 1999 Aug; 12(4):349-54. PubMed ID: 10493612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]